Audited Financial Results for the quarter and year ended 31st March, 2026
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma reported consolidated revenue of ₹40,783 million for FY26, down ~8% from ₹44,295 million in FY25, reflecting pressure on its pharma business. Profit after tax fell 24.7% to ₹14,185 million from ₹18,834 million, driven by higher other expenses (₹12,641 million vs ₹9,492 million) and a persistent loss in the Agro Chemicals segment. The company completed acquisition of 35.75% stake in Adcock Ingram Holdings Limited (South Africa) for ~₹19,912 million, recognised as an associate, contributing ₹466 million share of profit. A deferred tax asset of ₹1,150 million was recognised due to adoption of lower tax regime. EPS fell to ₹79.20 from ₹105.26. Auditors issued an unmodified (clean) opinion on both standalone and consolidated results.
Revenue and PAT both declined year-on-year, with PAT falling close to 25%, signalling margin pressure despite positive operating cash flow of ₹17,683 million. The Adcock Ingram acquisition adds international scale but the core pharma business faces headwinds.